Foghorn co-founder resigns from board; Guardant and Merck KGaA team up again

01 Sep 2022
endpts.com
Cigall Kadoch has won an appointment as an investigator at the Howard Hughes Medical Institute — and subsequently will be resigning from Flagship’s Foghorn Therapeutics board. Kadoch, who co-founded Foghorn in 2016, will continue working with the company, but as a scientific advisor. Foghorn CEO Adrian Gottschalk said in a prepared statement: Foghorn, however, is facing trouble as its partial clinical hold on a blood cancer treatment was converted into a full clinical hold in August. The initial hold came in May after a patient died in Foghorn’s early stage trial for FHD-286. The drug is meant to target two key proteins of the “BAF complex,” and is part of Foghorn’s bigger picture to treat cancer by drugging chromatin, or packaged DNA. — Lei Lei Wu BRIM Biotechnology, which recently listed on a Taiwanese stock exchange, has announced a seasoned equity offering to fund a Phase III trial for its dry eye treatment. The biotech will be offering NTD 500-600 million, or approximately $17-20 million USD, in common stock. One week after it went public in June, the biotech reported that its eye drops had shown “promising results” in a Phase II study — though it whiffed on the primary endpoint. That study was conducted on 220 patients in the US but did not show statistically significant improvement in corneal repair or patient-reported outcomes. The biotech highlighted that the study had statistically significant results in a few secondary measures. Regardless, the biotech will be moving forward with its Phase III study on its lead candidate BRM421, and it has a meeting lined up with the FDA later this year to discuss that prospect. — Lei Lei Wu Palo Alto-based Guardant Health has expanded its tie-up with German biotech Merck KGaA. The California cancer screening and testing company will offer up its real-world evidence know-how to “accelerate development” work on its partner’s precision oncology drugs, the companies said Wednesday. Applying to “core cancer indications with significant unmet need,” the collaboration expands upon previous work the pair has done together. The life sciences tech company developed its biomarker detection tool GuardantOMNI in collaboration with Merck KGaA and a host of other biopharma partners, including the other Merck, Pfizer, AstraZeneca and Bristol Myers Squibb. Merck KGaA’s researchers will team up with Guardant’s data scientists to tap into genomics and clinical information, the companies said. — Kyle LaHucik
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.